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Abstract
Thermal injury triggers a fulminant inflammatory cascade that heralds shock, end-organ failure, and ultimately sepsis and
death. Emerging evidence points to a critical role for the innate immune system, and several studies had documented
concurrent impairment in neutrophil chemotaxis with these post-burn inflammatory changes. While a few studies suggest
that a link between neutrophil motility and patient mortality might exist, so far, cumbersome assays have prohibited
exploration of the prognostic and diagnostic significance of chemotaxis after burn injury. To address this need, we
developed a microfluidic device that is simple to operate and allows for precise and robust measurements of chemotaxis
speed and persistence characteristics at single-cell resolution. Using this assay, we established a reference set of migration
speed values for neutrophils from healthy subjects. Comparisons with samples from burn patients revealed impaired
directional migration speed starting as early as 24 hours after burn injury, reaching a minimum at 72–120 hours, correlated
to the size of the burn injury and potentially serving as an early indicator for concurrent infections. Further characterization
of neutrophil chemotaxis using this new assay may have important diagnostic implications not only for burn patients but
also for patients afflicted by other diseases that compromise neutrophil functions.
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Introduction
In the United States, 40,000 patients are hospitalized with
severe burn injury annually[1]. Although goal-directed resuscita-
tion [2–4], early burn wound excision and grafting [5–8], and
recognition of burn hypercatabolism [9–11] have dramatically
improved outcomes for these patients, the mortality rate from
burn injury has changed little over the past twenty years, hovering
at 5–10% [1,12]. Among factors responsible for patient outcomes,
sepsis delivers the most profound impact, and contributes to 75%
of deaths [13,14]. Additionally, sepsis poses special diagnostic
challenges in the burn population, whose chronic inflammatory
state renders the usual clinical signs of infection – leukocytosis,
fever, and tachycardia –nonspecific and unreliable [15]. The
critical influence of infection on patient outcomes, as well as the
diagnostic difficulties that arise in the burn population, call for new
modalities in the identification and characterization of sepsis in
burn patients.
Multiple studies have documented impairments in neutrophil
function after burn injury, with potential implications for the
development of sepsis [16–23]. Flow cytometry analysis of
neutrophils reveals impairments in phagocytosis, bactericidal
activity, phago-lysosomal activity, and the oxidative burst within
two weeks post-injury [24]. Neutrophils demonstrate impaired
adhesion and complement receptor expression after burn injury
[25–31], and these changes, in turn, correlate with an increased
incidence of abscess formation in vitro [32]. In 1975, Warden et al.
evaluated the chemotaxis function of neutrophils from 46 burn
patients with a Boyden chamber assay, and compared the results
with those of 44 healthy volunteers [17]. In all cases, patients had
defective chemotaxis indexes and, within 72 hours after burn
injury, the degree of impairment correlated with burn size and was
predictive of mortality from septic complications [17,33]. One
limitation of this and other studies using the Boyden assay is the
lack of direct observation of the moving cells. The outcome of the
Boyden assay is a chemotactic index that depends on the size of
initial cell population, the fraction of cells that moves, and their
speed, directionality, and persistence. Consequently, these studies
could not identify the source of the changes in neutrophil
chemotaxis after burn injuries, or if one or more the chemotaxis
parameters have changed at the same time. More detailed analysis
using Zigmond assay that allows the examination of chemotaxis by
direct observation of individual neutrophils, suggested that
directionality of migration but not migration speed correlate with
the overall magnitude of burn injuries [18]. Overall, despite
evidence suggesting a link between neutrophil chemotaxis and
outcomes after burn injury, existing assays for neutrophil
migration are difficult to implement in the clinical setting, and
as such, the prognostic potential of chemotaxis measurements
remains largely unexplored.
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opportunities for cell based assays for clinical research applica-
tions, ranging from AIDS diagnostic [34], to trauma [35] and
cancer monitoring [36]. Specifically for chemotaxis applications,
after the first reported neutrophil chemotaxis measurements with
a microfluidic device [37], more devices for analyzing neutrophil
migration in response to opposing chemoattractant gradients
[38], temporal changes of the gradients [39], radialy evolving
gradients [40], and overlapping spatial stimuli [41] have been
reported. A broad range of applications, from the study of
unexpected neutrophil ability to migrate in certain conditions
against chemoattractant gradients a.k.a. fugetaxis [42], to
practical devices for on-chip isolation of neutrophils from a drop
of blood [43], and testing of new compounds modulators of
inflammation response [44] were enabled by the use of
microfluidic devices. Unfortunately, while these microfluidic
assays have permitted sophisticated experimentation in the
laboratory, they are difficult to implement in the clinical setting.
New designs are needed to overcome practical obstacles, like the
requirement for expensive syringe pumps or specialized training
of the operator.
To address the need for a robust, yet practical assay to
investigate the details of neutrophil chemotaxis in burn patients,
we designed a no-flow microfluidic device to measure the
directional migration speed in chemoattractant gradient, with
high throughput, and at single cell resolution. We validated the
device by measuring the migration speed of neutrophils in blood
samples from healthy volunteers and established one reference
value for healthy persons regardless of age and sex. We also
employed this device to document the impairment of neutrophil
migration speed after burn injury with a degree of precision
previously unattainable. We found that neutrophil motility is
depressed as early as 24 hours after the burn injury and is
inhibited the most at three to five days after injury. We found that
the degree of neutrophil directional migration speed inhibition in
burn patients correlates with the magnitude of burn trauma.
Surprisingly, the migration speed did not correlate with clinical
parameters frequently used to monitor these patients, e.g. absolute
neutrophil numbers, age of circulating neutrophils, or the body
temperature. These results suggest more complex relationships
between the impaired neutrophil chemotaxis and the clinical
evolution of the burn patients could be uncovered in further
studies.
Methods
Fabrication of the microfluidic devices
Microfluidic devices used to measure neutrophil directional
migration speed in response to chemoattractant gradients were
manufactured using standard techniques. Two layer of photoresist
(SU8, Microchem, Newton, MA), the first one 3 mm thin and the
second one 50 mm thick, were patterned on one silicon wafer by
sequentially employing two photolithography masks and process-
ing cycles according to the instructions from the manufacturer.
The wafer with patterned photoresist was used as a mold to
produce PDMS (Polydimethylsiloxane, Fisher Scientific, Fair
Lawn, NJ) parts, which were then bonded irreversibly to standard
glass slides (163 inches, Fisher). Up to six devices were bonded
side by side on one glass slide and transported to the clinic in
sealed Petri-dishes.
Sample preparation
Blood samples of 1 mL were obtained from healthy volunteers,
aged 18 years and older, who were on no immuno-suppressants. A
maximum of three samples were drawn from each volunteer, with
a time lapse of at least one week between draws. Additionally,
blood samples of 1 mL were drawn from burn patients admitted to
the Massachusetts General Hospital (MGH) and Shriners’ burn
units. Patients were enrolled if they sustained burns covering at
least 20% of their total body surface area. The first sample was
obtained within 72 hours after burn injury, and two more samples
were drawn at 48 hour intervals afterward. No sample was drawn
within 24 hours of an operative procedure. All patient samples
were obtained with written informed consent, and through
procedures approved by the MGH and Shriners Institutional
Review Boards.
Neutrophil isolation
Using sterile technique, neutrophils were isolated from whole
blood by density gradient separation using Polymorphprep (13.8%
sodium diatrizoate and 8.0% polysaccharide, Axis-Shield, Rode-
lokka, Oslo, Norway), with centrifugation at 500 g for 40 minutes.
To return the cells to an isotonic environment, they were
harvested and re-suspended in 10 mL of 0.56PBS, then isolated
by centrifugation at 400 g for 10 minutes. The final aliquot of
neutrophils were re-suspended in 50–100 mLo f1 6 PBS before
loading into the chemotaxis device. Samples were processed within
one hour after each blood draw, and were maintained at 37uC.
Neutrophil chemotaxis measurements
15 minutes before neutrophils were loaded, the microfluidic
device was primed with the chemokine fMLP [100 nM] and
the extracellular matrix protein fibronectin [100 mM]. For this, a
1 mL syringe filled with the solution of fMLP and fibronectin was
connected to one port of the device, and the outlet port was
blocked. By applying pressure to the syringe, the solution
was instilled into the device, and the displaced air diffused out
through the PDMS. Neutrophils were then infused into the
device and allowed to settle in the main channel by clamping the
ports of the device. Neutrophil migration in the direction of
chemoattractant started immediately, and was recorded using
and time-lapse imaging and 206 magnification on a Zeiss
Axiovert microscope (Fig. 1a). At least 50 neutrophils were
manually tracked in each sample, and velocities were calculated
using Image J (NIH). Separate experiments to characterize the
formation of gradients inside the device in the absence of
neutrophils were performed by replacing the fMLP with
fluorescein (Sigma) of comparable molecular weight, and
analyzing the distribution and changes in fluorescence intensity
from time-lapse imaging.
Statistical analysis
To test the normality of the distribution of migration speed
values for neutrophils in the same sample we employed the
Shapiro-Wilk test, indicating if the data is likely to be derived from
a normally distributed population (p.0.05). Correlations between
neutrophil migration speed and clinical parameters were calculat-
ed using multivariate analysis.
Results
To measure neutrophil migration speed in response to soluble
chemoattractants, we designed a microfluidic device that estab-
lishes chemokine gradients between a central, buffer-filled channel
that acts as a sink, and an array of smaller side channels that act as
chemoattractant reservoirs. The side channels communicate with
the central channel at one end, and are closed at the distal end
(Fig. 1). Priming the device with chemoattractant fills these side
Neutrophil Chemotaxis Assay
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solution in which neutrophils are suspended replaces chemokine
from the central channel. At the same time, most of the
chemoattractant in the array of side channels remains in these
channels secondary to their high length to cross section area ratio.
When the flow of buffer and neutrophils ceases, progressive
diffusion of the chemoattractant establishes a gradient in the
longitudinal direction of the side channels (Fig. 2). Neutrophils
from the central channel will follow this gradient and enter the side
channels. Moving neutrophils are mechanically confined in the
6 mm width, 3 mm height channels, and consequently, neutrophils
obstruct the channels and trap chemoattractant distally, creating
Figure 1. Overview of the neutrophil chemotaxis device. a. Microfluidic devices mounted on glass slides are observed on a microscope stage.
In this picture, six chemotaxis devices are aligned side by side on the same glass slide. The left most device has inlet and outlet tubing attached and is
filled with green fluorescent dye. b. Schematic of the microfluidic device. The device consists of a larger main channel and an orthogonal array of
smaller channels. In the first step, the whole device, including the side channels, is primed with the chemoattractant solution. In the second step,
neutrophils suspended in buffer are introduced in the main channel, washing out the chemoattractant from the main channel. The chemoattractant
gradient is established by diffusion, in the longitudinal direction of the side channels, between the end of the side channels filled with
chemoattractant and the main channel filled with buffer. Neutrophils inside the main channel follow a chemoattractant gradient and enter an array of
side channels, where their chemotaxis migration speed is measured.
doi:10.1371/journal.pone.0011921.g001
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neutrophils.
Device validation
Most of the neutrophils maintain constant speed toward fMLP
within the channels for at least the first 10 minutes (Fig. 3 and
Movie S1). Interestingly, a few neutrophils moved faster for the
first 100 mm inside the channels, decelerated later, and
maintained constant speed thereafter (Fig. 3b). Moving neutro-
phils displayed persistent behavior along the channels, with no
changes in the direction of migration. In one experiment, we
calculated the average speed of all cells and verified the normality
of distribution around the mean of the velocities of the almost 800
cells moving through the side channels (Fig. 3b, insert). We also
Figure 2. Visualization of the chemical gradients along the side channels. a. Linear gradients, formed along the side channels, were imaged
using fluorescent dyes of molecular weight comparable with that of the chemoattractant. Starting immediately after replacing the solution in the
main channel with buffer, quantitative fluorescence was measured along the array of side channels at 10, 30 and 60 minutes. These measurements
demonstrate the relative stability of the linear chemoattractant gradient over time. b. At 30 minutes after introducing the buffer, a linear gradient of
fluorescent dye can be visualized along the side channels. The height of the main channel (to the left) is larger that that of the side channels and
accounts for the apparent higher fluorescence of the main channel compared to the side channels.
doi:10.1371/journal.pone.0011921.g002
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200 cells randomly chosen at different locations throughout the
device. We observed no statistically significant difference between
the four populations and in subsequent experiments we analyzed
only 50 moving neutrophils, at random locations throughout the
device. In additional control experiments, in the absence of fMLP
chemokine, neutrophils did not migrate through the side channels
of the device. Furthermore, when a sample of neutrophils was
diluted ten-fold, the measured average migration speed was
unchanged (1766 mm/min and 1864 mm/min, p=0.3),suggest-
ing that migration speed was independent of the concentration of
neutrophils in the device.
Figure 3. Neutrophil migration inside the array of channels. a. Neutrophils enter the array of channels and move along the channels towards
higher concentrations of chemoattractant – see also Movie S1. b. Displacement of neutrophils vs. time inside the array of channels. For the first 10
minutes after entering the side channels neutrophil display remarkably uniform migration speed. Insert shows the distribution of average speed of
migration for 800 neutrophils from one healthy donor.
doi:10.1371/journal.pone.0011921.g003
Neutrophil Chemotaxis Assay
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donors
A total of 23 blood samples were collected from 18 healthy
volunteers aged 19–68 years (mean 40 years) (Table 1); 61% of
volunteers were female, and 39% male. Volunteers had no past
medical history with the exception of hypertension, hypothyroid-
ism, and depression. The most common medications taken were
oral contraceptives and antidepressants. No volunteer took
immunosuppressant drugs. Average neutrophil migration speed
for all volunteer samples was 1865 mm/min (range 14 to 24 mm/
min) (Fig. 4a). This average is within the limits of previously
reported values for normal neutrophil speed measured by standard
techniques [17]. To verify the reproducibility of our neutrophil
migration speed measurements, we repeated experiments with
neutrophils isolated from 4 healthy volunteers, with samples drawn
between one week and one month apart. The experiment yielded
equivalent neutrophil velocities, thus suggesting high reproduc-
ibility (Fig. 4b, p$0.05 in all cases). There were no correlations
between the neutrophil migration speed and the volunteer age or
gender (Fig. 4c).
Neutrophil migration in blood samples from burn
patients
Neutrophil motility was measured in a total of 24 samples from
2 pediatric and 6 adult patients (mean age 23 years, range 1–48
years) after sustaining 20–60% TBSA burns (Table 1); 63% of
patients were male, and 38% were female. The most common co-
morbidities were depression and hypertension. No patient took
immunosuppressant drugs. Across the entire data set, the average
neutrophil migration speed in burn patients was 966 mm/min,
significantly lower than in controls (p,0.01). In patients who were
not bacteremic at 72–120 hours post-injury, neutrophil migration
speed was negatively correlated with severity of burn injury
(Fig. 5a,R
2=0.6). Across the entire data set for burned patients,
there was poor correlation between neutrophil migration speed
and temperature (R
2=0.2) (Fig. 5b), absolute neutrophil count
(R
2=0.23), or the percentage of band cells in the neutrophil
population (R
2=0.01) (Fig. 6). Neutrophil motility was most
depressed between 72 and 120 hours after injury (Fig. 7), with an
average migration speed of 862 mm/min. After this time frame,
neutrophils demonstrated a tendency toward motility recovery,
with an average migration speed of 1163 mm/min one week after
the burn injury. One exception to this pattern was a 42 year-old
male who sustained 60% TBSA burns, who had positive sputum
cultures for Haemophilus influenzae and blood cultures positive for
Acinetobacter at the time his neutrophils were analyzed. No other
patient had documented bacteremia at the time of enrollment. A
second exception was a 2 year-old female patient who sustained
52% TBSA flame burns, whose neutrophil motility continued to
decline at the third blood draw. This patient had persistently high
fevers for up to two weeks after her initial burn injury, prompting
institution of empiric antibiotics. Despite broad antibiotic
coverage, she developed bacteremia with Enterococcus three weeks
after her initial insult.
Discussion
We have developed and validated a microfluidic device for the
quantitative analysis of neutrophil directional migration speed in
the clinical setting. The device utilizes small volumes of blood, a
practically important feature to avoid iatrogenic anemia by
repeated blood draws from critically ill or pediatric patients. The
assay yields data in less than three hours, and requires only the
sequential injection of two solutions through the same port of the
device, without syringe pumps or complicated priming. The assay
provides temporal information at the single-cell level, and while
most of the neutrophils migrate at steady speed along distinct
channels of our device, their migration speed can be measured to a
degree of precision difficult to attain by standard methods. A
comparison between this assay and other techniques based on
traditional or microfluidic technologies, is presented in Table 2.
For example, the Boyden chamber [45], which for decades served
as the standard laboratory technique for evaluating chemotaxis,
can only provide an overall measure of the chemotaxis function
and cannot quantify the contribution of changes in migration
Table 1. Clinical overview of burn patients’ data.
Volunteers Patients
No. Participants 18 8
Average Age in Years (Range) 40
(19–68)
31
(1–56)
Female
(%)
11
(61)
2
(25)
Male
(%)
7
(39)
6
(75)
Caucasian
(%)
17
(94)
5
(63)
Hispanic
(%)
03
(37)
Asian
(%)
1
(6)
0
No. without Comorbidities
(%)
10
(56)
5
(63)
Comorbidities
(in descending order of
frequency)
Depression
Hyperlipidemia
Hypertension
Hypothyroidism
Depression
Hyperlipidemia
Hypertension
Cirrhosis
Medications
(in descending order of
frequency)
Oral contraceptives
SSRIs
ACE Inhibitors
Diuretics
Thyroid replace-
ment therapy
Statins
Proton pump
inhibitors
ACE Inhibitors
Benzodiazepines
No. with Inhalation Injury
(%)
N/A 3
(13)
No. Requiring Mechanical
Ventilation (%)
N/A 13
(54)
No. with Positive Blood
Cultures ,72 hrs
Post-Burn (%)
-Microbes-
N/A 1
(13)
-Acinetobacter-
No. with Positive Blood
Cultures 1–4 Weeks
Post-Burn (%)
-Microbes-
N/A 4
(50)
-Enterococcus, MRSA,
MSSA, Enterobacter,
Candida-
No. with Positive Sputum
Cultures ,72 hrs
Post-Burn (%)
-Microbes-
N/A 2
(25)
-MSSA, H. influenzae-
No. with Positive Sputum
Cultures 1–4 Weeks
Post-Burn (%)
-Microbes-
N/A 2
(25)
-E. coli, MRSA-
doi:10.1371/journal.pone.0011921.t001
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PLoS ONE | www.plosone.org 6 July 2010 | Volume 5 | Issue 7 | e11921Figure 4. Neutrophil motility in healthy donors. a. Average neutrophil motility in 18 healthy donors. Samples were rearranged in decreasing
order of the average motilities. Bars represent standard error of the mean. The motility of at least 50 neutrophils was calculated for each sample. b.
Validation of the repeatability of neutrophil motility. Two samples from the same healthy donors were collected at two weeks time interval and
neutrophil migration speed measured in the microfluidic devices. c. Distribution of average values for neutrophil motility with the age of healthy
donors. No significant changes in neutrophil motility were observed with increasing age of the healthy volunteers. No significant differences were
observed between female and male donors (filled and empty dots, respectively).
doi:10.1371/journal.pone.0011921.g004
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chemotaxis function in various context. While being easy to use, it
also requires large numbers of cells, separated from several
milliliters of blood, disallows direct visualization of individual cells,
and cannot differentiate between chemotaxis and random cell
motility. More sophisticated assays, such as the Zigmond and
Dunn chambers [46,47], permit examination of individual cells
motility and are frequently used in biology laboratories. However,
the setup and use of these chambers are labor intensive, require
expertise and do not translate easily to the bedside. Recently,
microfluidic devices have higher precision of the chemoattractant
gradients forming inside [37–39]. These assays require only small
number of cells, translated into the need for smaller blood samples,
but their use relies on external pumps and trained operators. Like
other assay where neutrophils move on flat surfaces [37,39,42,46–
51], they also require parametric analysis of the ‘‘biased random
walk’’ migration pattern characteristic of neutrophils [52]. While
the gradients in our device are not as stable as in other microfluidic
flow devices [37], neutrophils moving inside the small side
channels of are exposed to steeper differences in chemoattractant
concentrations, which could partially explain the observed robust
chemotaxis in such devices [53]. Finally, the mechanical
confinement of neutrophils in small channels in this and other
devices [53,54], appears to facilitate the persistent movement and
has practical consequences the ease of quantification of motility.
Using the new assay, we established a normal range of
neutrophil directional migration speed values for healthy volun-
teers. Our volunteer studies using the device have yielded an
Figure 5. Correlations between neutrophil motility and clinical parameters in burn patients. a. We observed significant correlations
between neutrophil motility at 72 hours after burn injury and total burn surface area (R
2=0.6). b. No significant correlation was found between
neutrophil motility and the temperature in burn patients (R
2=0.2). Samples from the same patient are coded using the same symbol.
doi:10.1371/journal.pone.0011921.g005
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18 mm/min, establishing a benchmark value for neutrophil
motility towards fMLP in healthy persons. The average neutrophil
migration speed was in accordance with data from standard
chemotaxis assays. We also found no dependence of the average
neutrophil speed on the sex or age of the donor. Moreover, we
documented the reproducibility of the measurements by repeating
the experiments in four of the volunteers at one- to two-week time
intervals. Together, these results establish the assay as a valuable
tool for measuring neutrophil motility, and provide a reference set
of values characteristic of neutrophils from healthy subjects.
The assay is sensitive enough to detect significant impairment of
neutrophil migration speed as early as 24 hours after patient
admission to the hospital. This finding is new, and earlier studies
using traditional assays did not report any changes in neutrophil
chemotaxis until 72 hours e.g. Solomkin et al using an under-agar
assay [22], Chalain et al using an variation of Boyden assay [55],
Kim et al using a Zigmond assay [18]. The ability to measure
precisely the neutrophil migration speed independently of all the
other parameters of chemotaxis, also allowed us to establish a
strong correlation between the depression of migration speed at
72 hours after burn correlated and the total body surface area
(TBSA) of burn injury. In contrast, earlier studies have only been
able to identify correlations between the chemotaxis index as
measured by the Boyden chamber and TBSA [16], and at least
one other study found no correlation between TBSA and motility
[18]. One source for the differences could have been the fact that
most current assays measure a global chemotaxis index that
depends on multiple aspects of neutrophil migration, including the
fraction of the neutrophil population that are able to move, the
Figure 6. Correlations between neutrophil motility and neutrophil counts in burn patients. a. No significant correlation was found
between neutrophil motility and the absolute neutrophil count (R
2=0.2). b. Also, there was no significant correlation between average neutrophil
motility and percentage of band cells in the neutrophil population (R
2=0.01).
doi:10.1371/journal.pone.0011921.g006
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towards chemoattractant gradients. Together, these new findings
enabled by the microfluidic assay could contribute to better
understanding of the context of neutrophil pathology associated
with the burn injury and its contribution to the septic and other
complications in burn patients.
One more interesting observation in our study was the
correlation between the timing of most pronounced depression
of neutrophil migration speed that was measured at 48 hours after
the first therapeutic measure. One could speculate on the temporal
relationship between the aggressive fluid resuscitation, common
among all patients, which was started in the days and hours
preceding the first blood draw, with a total body balance in excess
of liters. By the second blood draw in all cases, resuscitation efforts
had concluded, and patients received crystalloid infusions at one-
to two-times their maintenance rate (as calculated by ideal body
weight). The immuno-modulatory effects of massive crystalloid
resuscitation have been described and large-volume infusions of
isotonic fluids were found upregulate the neutrophil oxidative
burst, increase expression of adhesion molecules, and induce
cellular injury [56]. Inappropriate activation of neutrophils after
crystalloid administration, evaluated in vitro, has been hypothesized
as a possible mechanism for ARDS and end-organ injury in
trauma patients [56]. Studies have also established increased rates
Figure 7. Changes in neutrophil motility in burn patients. Average neutrophil motility in individual patients was measured at 48 hours
intervals after admission to the hospital. Lower values for neutrophil migration speed compared to healthy volunteers (dashed gray line) were
recorded as early as 24 hours after burn injury for the majority of the patients. Insert shows the changes in average neutrophil migration speed for all
patients, with respect to the time of injury.
doi:10.1371/journal.pone.0011921.g007
Table 2. Comparison of technologies for measuring neutrophil chemotaxis.
Single Cell
Resolution Small Sample Size Ease of Use Pumps Required References
Traditional Assays
Transwell - - yes - [45]
Micropipette yes yes - yes [49]
Dunn, Zigmond Chambers yes yes - - [46,47]
Under-Agarose - - yes [60]
Microfluidic Assays
Gradient under Flow yes yes - yes [37–39,42–44,50,51,61]
Diffusion Chambers yes yes - - [40,48,62–64]
Convection-Free Channels yes yes - yes [41,53,54,65,66]
This assay yes yes yes - -
doi:10.1371/journal.pone.0011921.t002
Neutrophil Chemotaxis Assay
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patients who receive transfusions perioperatively [57] suggestive
for transfusion-related immunosuppression. Despite these effects,
few data exist on individual neutrophil responsiveness to
chemoattractant after crystalloid resuscitation. The depression in
neutrophil migration speed observed among this cohort of patients
may provide a window into the possible link between crystalloid
resuscitation and neutrophil migration.
A key goal for further studies will be to establish if neutrophil
motility is a more reliable diagnostic or prognostic indicator of
infection among burn patients than the nonspecific parameters of
white blood cell count and fever. Despite the profound role that
sepsis plays in the morbidity and mortality of burn patients,
standard clinical and laboratory markers of infection are unreliable
in the setting of severe burn injury [58]. For most clinical
conditions, fever, leukocytosis, tachycardia, increased respiratory
rate, and hypotension signal the onset of sepsis. In the burn
population, however, the massive inflammatory cascade that
follows thermal injury, coupled with insensible volume losses,
trigger these findings even in the absence of infection. The
dilemma is so profound that in 2007, the American Burn
Association published a consensus statement that condemned the
peripheral white blood cell count as an appropriate diagnostic
criterion for sepsis in burn patients [15]. Our preliminary results
suggest that preservation of neutrophil chemotaxis in burn patients
may correspond with bacteremia, and may signal the need for
antibiotic therapy in the absence of culture data. All but one
patient demonstrated depressed neutrophil motility compared with
controls, with maximal depression at 3–5 days post-injury. Of
these patients, most (60%) developed delayed infection, i.e.,
pneumonia or bacteremia several weeks after analysis. Those
patients who did not have delayed infection documented by
culture data, were still treated empirically with antibiotics for
suspected infection. The one patient whose motility did not follow
this pattern, and who in fact maintained supra-normal to normal
neutrophil migration speed, was a 42 year-old male with 60%
TBSA burns who had positive blood and sputum cultures on
admission to the burn unit. He was the only patient who had
documented infection by culture data at the time of neutrophil
analysis. Based on this preliminary data, it is possible that
maintenance of normal neutrophil motility in the acute phase after
burn injury corresponds with active bacterial infection. As cultures
require at least 48 hours for results, neutrophil motility may
provide an earlier confirmatory marker of sepsis than current
methods. This potential would be particularly useful for targeting
patients who require antimicrobial therapy during in an era when
resistance of microbes to pharmacologic agents continues to
escalate.
In conclusion, we designed a microfluidic device that allows for
robust measurements of neutrophil motility at single-cell resolu-
tion. We applied this device to neutrophils isolated from healthy
volunteers and established a range of normal values for neutrophil
migration. We further validated the new technique for measu-
ring neutrophil chemotaxis speed through repeated experi-
ments. When we applied the technique to neutrophils from burn
patients, we documented a significant reduction in average
neutrophil migration speed and the dynamic evolution of
neutrophil migration impairment. The ability to screen large
numbers of neutrophils at single-cell resolution could allow for the
study of cell phenotype under various clinical circumstances.
Simple comparisons between patients and the healthy average
could provide insight into management of immune diseases that
alter neutrophil function via point-of-care microfluidic devices.
Modulation of the immunosuppressant regimen in transplant
recipients, risk of infection among chemotherapy patients,
influence of hemorrhage and massive transfusion after trauma,
pathophysiology of Chediak Higashi syndrome and chronic
granulomatous disease [59], or cellular changes in sepsis and
ARDS, all represent potential avenues of clinical research to which
chemotaxis data may contribute. Furthermore, quantitative
analysis of neutrophil chemotaxis could optimize recommenda-
tions for immuno-modulatory and antibiotic therapies, and
ultimately improve outcomes in patients suffering from severe
burn injury and other immune-suppressed states.
Supporting Information
Movie S1 Human neutrophils migrating inside the array of
channels. Neutrophils, isolated from a healthy volunteer, enter the
array of channels and move towards higher concentrations of
chemoattractant fMLP [100 nM]. Individual images recorded
every minute for ten minutes were combined in a time-lapse movie
showing the migration of three representative neutrophils through
the channels. The width of the channels is 6 mm.
Found at: doi:10.1371/journal.pone.0011921.s001 (2.04 MB AVI)
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